MGD Innovations Inc.

MGD Innovations Inc. (MGDi) is an ophthalmology-focused medical device company specializing in the diagnosis and treatment of meibomian gland dysfunction (MGD) and dry eye disease. The company's flagship offering is the Maskin® Meibomian Gland Probing (MGP) Protocol, a patented procedure that uses targeted probing to relieve encasing scar tissue (periductal fibrosis) around meibomian glands, thereby clearing blockages and restoring normal meibum secretion. Clinical data cited on their site demonstrates >75% reduction in dry eye symptoms and 92% of patients reporting symptomatic improvement within one week of treatment. The procedure is characterized by physical release of pressure within glands, often audible as a "POP." MGDi positions probing as a preparatory step before heat and pressure therapies to minimize further lid irritation. The company emphasizes that MGD affects 86% of dry eye patients (over 30 million US sufferers) and reports successful treatment of more than 20,000 patients. The Maskin Protocol is presented as the only proven method to safely open constricted glands while providing objective physical evidence and preventing gland atrophy. MGDi appears to operate a practitioner network and provides training and resources to eye care providers implementing the protocol.